Pennsylvania 2025-2026 Regular Session

Pennsylvania Senate Bill SB865

Introduced
6/18/25  

Caption

In miscellaneous provisions, further providing for urine drug screening requirement and providing for medetomidine awareness education.

Impact

The implications of SB865 extend into state laws concerning drug testing and medical education. If enacted, it would require healthcare facilities to comply with standardized urine drug screening protocols and initiate awareness programs focused on medetomidine. This change could potentially improve patient safety and clinical outcomes by ensuring that both patients and medical professionals are well-informed about the risks and proper handling of medetomidine.

Summary

SB865 proposes to implement specific requirements for urine drug screening and enhance educational efforts regarding medetomidine awareness. The bill seeks to standardize procedures around drug screening to ensure consistency and effectiveness across various healthcare settings. By addressing these facets, SB865 emphasizes the importance of monitoring and education concerning medetomidine, an anesthetic agent that has raised safety concerns in clinical use.

Sentiment

Overall sentiment surrounding SB865 appears to be favorable among healthcare professionals, who recognize the need for improved drug screening and education as critical elements in enhancing patient safety. Stakeholders argue that effective implementation of urine drug screening is necessary for identifying substance misuse early, while educational initiatives regarding medetomidine are essential to mitigate potential risks associated with its administration.

Contention

Despite the general support, there may be points of contention regarding the costs and logistics of implementing the standardized drug screening and educational programs. Some critics could raise concerns about whether the new requirements might place an undue burden on smaller healthcare facilities and how effectively these initiatives will be monitored and enforced. Additionally, discussions may arise about the adequacy of resources provided for education and training on medetomidine.

Companion Bills

No companion bills found.

Previously Filed As

PA SB683

In public safety, providing for urine drug screening requirement and for xylazine awareness education.

PA HB1690

In powers and duties of the Department of Drug and Alcohol Programs, providing for xylazine awareness education.

PA SB1290

In preliminary provisions, further providing for definitions; in patients, further providing for prohibitions; in miscellaneous provisions, further providing for protections for patients and caregivers and providing for enforcement and civil actions; and promulgating regulations.

PA HB1492

In miscellaneous provisions relating to emergency management services, providing for firefighter cancer screenings.

PA HB1869

In food protection, further providing for definitions, providing for food allergy awareness and further providing for powers of department.

PA HB984

In miscellaneous provisions, further providing for protections for patients and caregivers.

PA HB2236

In miscellaneous provisions relating to emergency management services, providing for insurance coverage for cancer and cardiovascular screenings for firefighters.

PA SB1204

In miscellaneous provisions relating to emergency management services, providing for health screenings for firefighters and EMS providers.

PA HB1880

In preliminary provisions, further providing for definitions; and, in miscellaneous, providing for release testing and reimbursement.

PA HB1377

In miscellaneous provisions, providing for Firefighter Cancer Registry.

Similar Bills

MD HB1109

Public Health - Medetomidine and Xylazine Consumer Protection Act

MD SB875

Public Health – Medetomidine and Xylazine Consumer Protection Act

DE SJR9

Designating August 31, 2025, As "international Overdose Awareness Day" In The State Of Delaware And Requiring The State Flag To Be Flown At Half-staff In Observance.